13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01838174
(ClinicalTrials.gov)
May 201318/4/2013A Trial of Neuroprotection With ACTH in Acute Optic NeuritisA Phase IV Trial of Neuroprotection With ACTH in Acute Optic NeuritisMultiple SclerosisDrug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids)University of Colorado, DenverMallinckrodt;University of PennsylvaniaTerminated18 Years55 YearsAll100Phase 4United States
2NCT00418145
(ClinicalTrials.gov)
September 20032/1/2007Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis AttacksOral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)Multiple SclerosisDrug: megadose oral methylprednisolone;Drug: IV methylprednisoloneFred LublinNational Multiple Sclerosis Society;PfizerTerminated18 Years50 YearsAll16Phase 3United States
3NCT00112034
(ClinicalTrials.gov)
June 200327/5/2005AVONEX® Combination Trial - ACTA Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.Multiple Sclerosis, Relapsing-RemittingDrug: Methotrexate;Drug: IV methylprednisoloneBiogen IdecNULLCompleted18 Years55 YearsBoth350Phase 4United States